Short‐Term Efficacy of Biologics in Recalcitrant Allergic Fungal Rhinosinusitis: A Systematic Review and Meta‐analysis
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1339 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2025. Verfasst von Yeon Hee Im und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Kore…. Hauptthemen laut MEDLINE: Sinusitis, Rhinitis, Allergic, Biological Products, Mycoses. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Research Foundation of Korea (NRF), Institute of Clinical Medicine Research of Bucheon St. Mary's Hospital.
Abstract (Originalsprache)
Objective
Allergic fungal rhinosinusitis (AFRS) is characterized by type I immunoglobulin E (IgE)‐mediated hypersensitivity reactions to fungal antigens. This systematic review and meta‐analysis assessed the efficacy of biologics in the management of refractory AFRS. Data Sources PubMed, SCOPUS, Embase, Web of Science, and Cochrane. Review Methods Changes in Sino‐Nasal Outcome Test (SNOT)‐22 scores, endoscopic findings, serum eosinophil count, and total IgE levels were assessed in patients with refractory AFRS after receiving biologic therapy. Subgroup analyses were conducted to evaluate the individual efficacy of each biologic agent, including dupilumab, mepolizumab, and omalizumab.
Results
A total of 60 patients from 6 studies were analyzed. Biologics showed a significant improvement in SNOT‐22 scores (standard mean difference 1.1607 [95% CI 0.5549; 1.7664]), endoscopic scores (2.1953 [1.4181; 2.9725]), serum eosinophil count (1.1649 [0.7735; 1.5563]), and total IgE level (1.0700 [0.4052; 1.7348]). Dupilumab, mepolizumab, and omalizumab all enhanced SNOT‐22 and endoscopic scores. Additionally, dupilumab significantly reduced total IgE levels (1.2981 [0.4063; 2.1900]), whereas both dupilumab (0.9274 [0.1592; 1.6957]) and mepolizumab (1.2324 [0.9215; 1.5433]) significantly lowered the serum eosinophil counts.
Conclusion
The agents significantly improved nasal symptoms, laboratory findings, and endoscopic scores. These findings support the potential role of biologics as a therapeutic option for patients with AFRS who are unresponsive to conventional treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
ORCID-Profile: Yeon Hee Im, Gulnaz Stybayeva, Se Hwan Hwang
Förderung
- National Research Foundation of Korea (NRF)
- Institute of Clinical Medicine Research of Bucheon St. Mary's Hospital
Zitieren
APA
Im, Y. H., Stybayeva, G., & Hwang, S. H. (2025). Short‐Term Efficacy of Biologics in Recalcitrant Allergic Fungal Rhinosinusitis: A Systematic Review and Meta‐analysis. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1339
Vancouver
Im YH, Stybayeva G, Hwang SH. Short‐Term Efficacy of Biologics in Recalcitrant Allergic Fungal Rhinosinusitis: A Systematic Review and Meta‐analysis. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1339
BibTeX
@article{Im2025,
author = {Im, Yeon Hee and Stybayeva, Gulnaz and Hwang, Se Hwan},
title = {Short‐Term Efficacy of Biologics in Recalcitrant Allergic Fungal Rhinosinusitis: A Systematic Review and Meta‐analysis},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1339}
}
EUVIMED